KOL Views: Early feedback on launches of first three anti-CGRP mAbs

Initial sales figures from Amgen and Novartis suggest that Aimovig (erenumab) has made strong initial progress in penetrating the migraine market, but it has recently been joined by two more anti-CGRP rivals in Eli Lilly’s Emgality (galcanezumab) and Teva’s Ajovy (fremanezumab).

To provide FirstWord readers with rapid feedback on a first-person experience with the drugs and the respective marketing efforts behind them, we are hosting an expert call with a key opinion leader (KOL) later this week.

Key topics that will be discussed during the call include, among other things… what was your sense of how the three marketed mAbs stacked up against one another based on the clinical data; has this changed at all based on your experience in the commercial setting; have you prescribed any/all of the three marketed mAbs; to what type(s) of patients have you prescribed mAbs so far; how do you decide among the mAbs; what were your expectations for how strong the demand would be and have you been surprised one way or the other; what sort of feedback have you gotten from patients; have you noticed any difference among the respective marketing efforts; and are there any data readouts or new approvals that will affect the way you will be prescribing mAbs?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the ongoing launch of anti-CGRP mAbs in the migraine setting.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.